Mutation rate of AmpC-β-lactamase-producing Enterobacterales and treatment in clinical practice : A word of caution
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com..
In a retrospective multicenter study of 575 patients with bloodstream infections or pneumonia due to wild-type AmpC β-lactamase-producing Enterobacterales, species with low in-vitro mutation rates for AmpC derepression were associated to fewer treatment failures due to AmpC overproduction (aHR 0.5, 95%CI 0.2-0.9). However, compared to cefepime/carbapenems using 3GC as definitive therapy remained associated with this adverse outcome (15% vs. 1%).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2024) vom: 25. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maillard, Alexis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AmpC β-lactamase |
|---|
| Anmerkungen: |
Date Revised 25.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciae160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370174054 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370174054 | ||
| 003 | DE-627 | ||
| 005 | 20240327000553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciae160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370174054 | ||
| 035 | |a (NLM)38527853 | ||
| 035 | |a (PII)ciae160 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maillard, Alexis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mutation rate of AmpC-β-lactamase-producing Enterobacterales and treatment in clinical practice |b A word of caution |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. | ||
| 520 | |a In a retrospective multicenter study of 575 patients with bloodstream infections or pneumonia due to wild-type AmpC β-lactamase-producing Enterobacterales, species with low in-vitro mutation rates for AmpC derepression were associated to fewer treatment failures due to AmpC overproduction (aHR 0.5, 95%CI 0.2-0.9). However, compared to cefepime/carbapenems using 3GC as definitive therapy remained associated with this adverse outcome (15% vs. 1%) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AmpC β-lactamase | |
| 650 | 4 | |a Antibiomicrobial therapy | |
| 650 | 4 | |a Enterobacterales | |
| 650 | 4 | |a bloodstream infection | |
| 650 | 4 | |a pneumonia | |
| 700 | 1 | |a Dortet, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Delory, Tristan |e verfasserin |4 aut | |
| 700 | 1 | |a Lafaurie, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Bleibtreu, Alexandre |e verfasserin |4 aut | |
| 700 | 0 | |a Treatment of AmpC producing Enterobacterales study group |e verfasserin |4 aut | |
| 700 | 1 | |a Azoulay, Elie |e investigator |4 oth | |
| 700 | 1 | |a Joseph, Adrien |e investigator |4 oth | |
| 700 | 1 | |a Molina, Jean-Michel |e investigator |4 oth | |
| 700 | 1 | |a Lafaurie, Matthieu |e investigator |4 oth | |
| 700 | 1 | |a Bercot, Béatrice |e investigator |4 oth | |
| 700 | 1 | |a Maillard, Alexis |e investigator |4 oth | |
| 700 | 1 | |a Paccoud, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Bleibtreu, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Robert, Jérôme |e investigator |4 oth | |
| 700 | 1 | |a Drieux, Laurence |e investigator |4 oth | |
| 700 | 1 | |a Bernier, Juliette |e investigator |4 oth | |
| 700 | 1 | |a Villa, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Maury, Éric |e investigator |4 oth | |
| 700 | 1 | |a Surgers, Laure |e investigator |4 oth | |
| 700 | 1 | |a Chopin, Dorothée |e investigator |4 oth | |
| 700 | 1 | |a Lalande, Valérie |e investigator |4 oth | |
| 700 | 1 | |a Tankovic, Jacques |e investigator |4 oth | |
| 700 | 1 | |a Delory, Tristan |e investigator |4 oth | |
| 700 | 1 | |a Contejean, Adrien |e investigator |4 oth | |
| 700 | 1 | |a Poupet, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Mouthon, Luc |e investigator |4 oth | |
| 700 | 1 | |a Baillard, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Escaut, Lélia |e investigator |4 oth | |
| 700 | 1 | |a Jaureguiberry, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Cuzon, Gaëlle |e investigator |4 oth | |
| 700 | 1 | |a Dortet, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Chaibi, Khalil |e investigator |4 oth | |
| 700 | 1 | |a El Alaoui, Fatma |e investigator |4 oth | |
| 700 | 1 | |a Zahar, Jean-Ralph |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2024) vom: 25. März |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciae160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 03 | ||